Our Pricing

Essential Guide: Getting Your 5th Mounjaro Pen Dose Right

Published on: June 03, 2026

Reaching your 5th dose mounjaro pen UK milestone typically marks an important transition in your treatment journey, often moving from the 5mg maintenance phase to 7.5mg escalation. Understanding proper dosing technique, timing, and what to expect during this transition ensures optimal treatment outcomes and helps minimise potential side effects as your body adjusts to the increased dose.

Understanding the Mounjaro Dose Escalation Schedule

Mounjaro (tirzepatide) follows a structured dose escalation protocol designed to optimise tolerability whilst achieving therapeutic effect [1]. The standard UK titration schedule begins with 2.5mg weekly for four weeks, followed by 5mg weekly for the next four weeks. Your fifth dose typically represents the start of week five, maintaining the 5mg level before potential escalation to 7.5mg at week nine, subject to prescriber assessment.

This graduated approach allows your gastrointestinal system to adapt progressively to tirzepatide's dual GIP/GLP-1 receptor agonist action [1]. In the SURPASS clinical programme, structured dose escalation significantly reduced the incidence of nausea and vomiting compared to immediate higher dosing, with most gastrointestinal side effects peaking during the first 8-12 weeks then declining substantially [2].

Your UK prescriber will determine the optimal escalation timing based on your weight loss progress, tolerability, and individual response. Some patients remain on 5mg longer if experiencing excellent results, whilst others progress to 7.5mg, 10mg, 12.5mg, or the maximum 15mg dose to achieve their target weight reduction goals [1].

Proper Injection Technique for Your 5th Mounjaro Pen

Each Mounjaro KwikPen contains a single pre-measured dose and should never be shared between patients, even with a changed needle. Before administering your fifth dose, inspect the pen window to ensure the solution appears clear and colourless — any cloudiness, discolouration, or visible particles means the pen should not be used and requires replacement.

Select an injection site on your abdomen (at least 5cm away from your navel), upper thigh, or upper arm. Rotate injection sites with each weekly dose to reduce the risk of lipohypertrophy (fatty lumps under the skin) and maintain consistent absorption. Clean the chosen area with an alcohol wipe and allow it to dry completely before injecting.

Remove the pen cap, position the pen perpendicular to your skin, and press firmly until you hear the first click. Continue holding the pen against your skin whilst counting slowly to ten — this ensures the full dose is delivered subcutaneously. You'll hear a second click and see the dose indicator return to zero, confirming successful injection [3].

Common Injection Mistakes to Avoid

Removing the pen too quickly represents the most frequent error, potentially resulting in incomplete dose delivery and suboptimal therapeutic effect. Always maintain firm pressure and count the full ten seconds, even after hearing the second click. Additionally, never inject into areas with visible bruising, scarring, or skin irritation, as this may affect absorption rates and increase discomfort.

What to Expect During the 5mg Maintenance Phase

The 5mg dose phase typically spans weeks five through eight of your Mounjaro treatment. During this period, many UK patients report continued steady weight loss, improved appetite control, and reduced food-related thoughts compared to the initial 2.5mg phase [1]. Clinical trial data shows that tirzepatide's weight reduction effects continue to increase progressively through week 72, with no plateau observed at intermediate doses [2].

Gastrointestinal side effects — including mild nausea, occasional constipation, or changes in bowel habits — often diminish significantly by the fifth dose as your body adapts to the medication's mechanism. However, some patients experience a temporary recurrence of these symptoms when escalating to 7.5mg, usually resolving within 2-3 weeks [2].

Average weight loss during the 5mg phase varies considerably between individuals, but SURPASS trial participants on 5mg tirzepatide achieved mean body weight reductions of approximately 15-16% over 40 weeks [1]. Your UK prescriber will monitor your progress through regular follow-up consultations to determine whether dose escalation is appropriate or whether remaining at 5mg provides optimal benefit-to-side-effect ratio for your circumstances.

Managing Side Effects at 5mg

If you experience persistent nausea, eating smaller, more frequent meals rather than three large meals can help considerably. Avoiding high-fat, greasy, or heavily spiced foods during the first few days after each injection may also reduce gastrointestinal discomfort. Stay well-hydrated, particularly if experiencing any diarrhoea, and contact your prescriber if side effects become severe or don't improve within a few weeks.

Transitioning from 5mg to 7.5mg: Timing and Considerations

The decision to escalate from 5mg to 7.5mg should always be made in consultation with your UK prescriber and typically occurs after completing at least four weeks at the 5mg dose. This transition isn't automatic — your prescriber will assess your weight loss trajectory, tolerability, any side effects, and how close you are to your target weight before recommending escalation [1].

Some patients achieve their weight loss goals on 5mg and may not require higher doses. In the SURPASS-1 trial, participants on 5mg tirzepatide achieved clinically significant weight reduction without escalation, demonstrating that lower doses can be highly effective for certain individuals [1]. Conversely, those with higher baseline BMI or more ambitious weight loss targets often benefit from progressing through the full dose range up to 15mg.

When escalating to 7.5mg, expect a similar adjustment period to when you first started Mounjaro. Mild gastrointestinal symptoms may temporarily return but typically resolve more quickly than during initial treatment, as your body has already adapted to tirzepatide's mechanism of action [2]. Your prescriber will schedule follow-up assessments to monitor your response and determine subsequent escalation timing if needed.

Storage and Handling of Your Mounjaro Pens

Unopened Mounjaro pens must be stored in a refrigerator between 2°C and 8°C, away from the freezer compartment. Never freeze Mounjaro — if a pen has been frozen, it must be discarded even if subsequently thawed, as freezing damages the tirzepatide molecule and renders it ineffective [3].

Once you've used a Mounjaro pen for your injection, it should be discarded immediately in a sharps container — these pens are designed for single use only and don't contain multiple doses. Store unused pens in their original carton to protect from light. If you're travelling, Mounjaro pens may be kept at room temperature (not exceeding 30°C) for up to 21 days, though refrigeration remains preferable when possible.

Always check the expiry date printed on the pen label before use. Expired medication should never be used, as potency cannot be guaranteed beyond the manufacturer's stated date. If you've missed a dose and it's been more than four days since your scheduled injection, contact your prescriber for guidance rather than doubling up or adjusting the schedule independently [3].

Travelling with Mounjaro in the UK

When travelling domestically or internationally, carry Mounjaro pens in your hand luggage with your prescription documentation. Use a medical cool bag with ice packs (not frozen solid) if refrigeration won't be available for extended periods. Airport security should be informed you're carrying prescription medication — the MHRA-licensed packaging and prescription label provide necessary documentation for UK travel.

Monitoring Progress and When to Contact Your Prescriber

Regular monitoring throughout your Mounjaro treatment ensures both safety and optimal outcomes. Your UK prescriber will schedule follow-up consultations to assess weight loss progress, review any side effects, check blood pressure, and determine appropriate dose escalation timing. Between appointments, tracking your weight weekly (same day, same time, similar conditions) provides valuable data for clinical decision-making.

Contact your prescriber immediately if you experience severe abdominal pain that doesn't resolve, persistent vomiting preventing fluid intake, signs of pancreatitis (severe upper abdominal pain radiating to the back), or symptoms of thyroid changes (lump in neck, persistent hoarseness, difficulty swallowing). Whilst serious side effects are uncommon, early identification and management are essential [2][3].

Additionally, reach out if you're not experiencing any weight loss after 8-12 weeks at therapeutic doses, as this may indicate Mounjaro isn't the optimal treatment for you. Alternative weight management medications available through Cured Pharmacy, such as Wegovy or Saxenda, work through different mechanisms and may be more suitable depending on your individual physiology and response profile. Your prescriber can discuss these options during your consultation.

Scientific References

1. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]
2. Rosenstock, J., Wysham, C., Frías, J. P., et al. (2021). Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. The Lancet, 398(10295), 143–155. https://doi.org/10.1016/S0140-6736(21)01324-6 [accessed 13 August 2026]
3. Electronic Medicines Compendium. (2024). Mounjaro 5 mg solution for injection in pre-filled pen – Summary of Product Characteristics. Retrieved from https://www.medicines.org.uk/emc/product/14298 [accessed 13 August 2026]
4. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
5. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
6. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Mounjaro is a prescription-only medicine licensed by the MHRA for weight management in adults with specific BMI criteria and must be prescribed following clinical consultation. Individual results may vary, and weight loss outcomes depend on multiple factors including diet, exercise, and adherence to treatment.